
Opinion|Videos|February 14, 2025 (Updated: January 31, 2025)
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
This segment explores Dr. Rossi's clinical experience with cilta-cel as a second-line therapy, focusing on its efficacy and quality-of-life benefits across diverse patient populations.
Advertisement
Video content above is prompted by the following:
- Can you share your experience with cilta-cel as a second-line therapy?
- What advantages in terms of efficacy and quality of life have you noted across various patient populations?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Elucidating Treatment Selection for Metastatic HSPC at ASCO GU 2026
2
Rolling NDA Submission Completed for Zipalertinib in EGFR+ NSCLC
3
Combatting Toxicities and Leveraging Novel Therapies in Lung Cancer Care
4
FDA Issues CRL for Retifanlimab/Chemotherapy in Metastatic NSCLC
5






























































